Skip to main content

Advertisement

SpringerLink
Log in

Changes of cerebrospinal fluid Aβ42, t-tau, and p-tau in Parkinson’s disease patients with cognitive impairment relative to those with normal cognition: a meta-analysis

  • Original Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

The cerebrospinal fluid (CSF) signature of reduced amyloid beta 1–42 (Aβ42), elevated total tau (t-tau), and phosphorylated tau181 (p-tau) is important for the early diagnosis of Alzheimer’s disease (AD). Aβ42, t-tau, and p-tau have been reported in numerous studies to contribute to predicting cognitive impairment in Parkinson’s disease (PDCI). However, no consistent conclusion can be drawn so far. Literatures regarding Aβ42, t-tau, and p-tau in CSF were systematically reviewed, and a meta-analysis was thus performed to evaluate the changes of these biomarkers in PDCI patients, including PD with mild cognitive impairment (PDMCI) and PD dementia (PDD) patients, relative to PD with normal cognition (PDNC) patients. Databases of “PubMed,” “EBSCO,” and “Springer” were retrieved for articles concerning Aβ42, t-tau, and p-tau in PDCI patients relative to those in PDNC patients published from January 1, 2000 to February 1, 2017. The following keywords were set, namely, “dementia” or “cognitive impairment” or “mild cognitive impairment” and “cerebrospinal fluid” and “Parkinson*.” Sixteen articles comprising 590 PDCI patients and 1182 PDNC patients were included. The results showed that CSF Aβ42 level in PDCI cohort was lower than that in PDNC cohort (pooled Std.MD = −0.44, 95% CI [−0.61, −0.26], p < 0.00001). Reduced Aβ42 (pooled Std.MD = −0.60, 95% CI [−0.75, −0.45], p < 0.00001) as well as elevated t-tau (pooled Std.MD = 0.21, 95% CI [0.06, 0.35], p = 0.006) and p-tau (pooled Std.MD = 0.36, 95% CI [0.02, 0.69], p = 0.04) could be observed in PDD cohort compared with PDNC cohort. Therefore, amyloid pathology and tauopathy may participate in the development of PDD, which is similar to AD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Santangelo G, Vitale C, Picillo M, Moccia M, Cuoco S, Longo K et al (2015) Mild cognitive impairment in newly diagnosed Parkinson’s disease: a longitudinal prospective study. Parkinsonism Relat Disord 21:1219–1226

    Article  PubMed  Google Scholar 

  2. Garcia-Ptacek S, Kramberger MG (2016) Parkinson disease and dementia. J Geriatr Psychiatry Neurol 29:261–270

    Article  PubMed  Google Scholar 

  3. Pfeiffer HC, Løkkegaard A, Zoetmulder M, Friberg L, Werdelin L (2014) Cognitive impairment in early-stage non-demented Parkinson’s disease patients. Acta Neurol Scand 129:307–318

    Article  CAS  PubMed  Google Scholar 

  4. Pedersen KF, Larsen JP, Tysnes OB, Alves G (2013) Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurol 70:580–586

    Article  PubMed  Google Scholar 

  5. Kotzbauer PT, Cairns NJ, Campbell MC, Willis AW, Racette BA, Tabbal SD et al (2012) Pathologic accumulation of alpha-synuclein and Abeta in Parkinson disease patients with dementia. Arch Neurol 69:1326–1331

    Article  PubMed  PubMed Central  Google Scholar 

  6. Recasens A, Dehay B, Bové J, Carballo-Carbajal I, Dovero S, Pérez-Villalba A et al (2014) Lewy body extracts from Parkinson disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol 75:351–362

    Article  CAS  PubMed  Google Scholar 

  7. Zhang QS, Heng Y, Yuan YH, Chen NH (2017) Pathological alpha-synuclein exacerbates the progression of Parkinson’s disease through microglial activation. Toxicol Lett 265:30–37

    Article  CAS  PubMed  Google Scholar 

  8. Olsson B, Lautner R, Andreasson U, Öhrfelt A, Portelius E, Bjerke M et al (2016) CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol 15:673–684

    Article  CAS  PubMed  Google Scholar 

  9. Terrelonge M, Marder KS, Weintraub D, Alcalay RN (2016) CSF beta-amyloid 1-42 predicts progression to cognitive impairment in newly diagnosed Parkinson disease. J Mol Neurosci 58:88–92

    Article  CAS  PubMed  Google Scholar 

  10. Bäckström DC, Eriksson Domellöf M, Linder J, Olsson B, Öhrfelt A, Trupp M et al (2015) Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease. JAMA Neurol 72:1175–1182

    Article  PubMed  Google Scholar 

  11. Liu C, Cholerton B, Shi M, Ginghina C, Cain KC, Auinger P et al (2015) CSF tau and tau/Abeta42 predict cognitive decline in Parkinson’s disease. Parkinsonism Relat Disord 21:271–276

    Article  PubMed  PubMed Central  Google Scholar 

  12. Stang A (2010) Critical evaluation of the Newcastle-Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605

    Article  PubMed  Google Scholar 

  13. Mollenhauer B, Trenkwalder C, von Ahsen N, Bibl M, Steinacker P, Brechlin P et al (2006) Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson’s disease dementia. Dement Geriatr Cogn Disord 22:200–208

    Article  CAS  PubMed  Google Scholar 

  14. Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D’Amore C et al (2008) Cerebrospinal fluid biomarkers in Parkinson’s disease with dementia and dementia with Lewy bodies. Biol Psychiatry 64:850–855

    Article  CAS  PubMed  Google Scholar 

  15. Compta Y, Marti MJ, Ibarretxe-Bilbao N, Junque C, Valldeoriola F, Munoz E et al (2009) Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson’s disease. Mov Disord 24:2203–2210

    Article  PubMed  Google Scholar 

  16. Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C et al (2010) CSF Abeta(42) and tau in Parkinson’s disease with cognitive impairment. Mov Disord 25:2682–2685

    Article  PubMed  PubMed Central  Google Scholar 

  17. Hall S, Öhrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F et al (2012) Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or Parkinsonian disorders. Arch Neurol 69:1445–1452

    Article  PubMed  Google Scholar 

  18. Maetzler W, Tian Y, Baur SM, Gauger T, Odoj B, Schmid B et al (2012) Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia. PLoS One 7:e48042

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Beyer MK, Alves G, Hwang KS, Babakchanian S, Bronnick KS, Chou YY et al (2013) Cerebrospinal fluid Abeta levels correlate with structural brain changes in Parkinson’s disease. Mov Disord 28:302–310

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Nutu M, Zetterberg H, Londos E, Minthon L, Nägga K, Blennow K et al (2013) Evaluation of the cerebrospinal fluid amyloid-beta1-42/amyloid-beta1-40 ratio measured by alpha-LISA to distinguish Alzheimer’s disease from other dementia disorders. Dement Geriatr Cogn Disord 36:99–110

    Article  CAS  PubMed  Google Scholar 

  21. Alves G, Lange J, Blennow K, Zetterberg H, Andreasson U, Førland MG et al (2014) CSF Abeta42 predicts early-onset dementia in Parkinson disease. Neurology 82:1784–1790

    Article  CAS  PubMed  Google Scholar 

  22. Vranová HP, Hényková E, Kaiserová M, Menšíková K, Vaštík M, Mareš J et al (2014) Tau protein, beta-amyloid(1)(−)(4)(2) and cluster in CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia. J Neurol Sci 343:120–124

    Article  PubMed  Google Scholar 

  23. Yarnall AJ, Breen DP, Duncan GW, Khoo TK, Coleman SY, Firbank MJ et al (2014) Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology 82:308–316

    Article  PubMed  PubMed Central  Google Scholar 

  24. Yu SY, Zuo LJ, Wang F, Chen ZJ, Hu Y, Wang YJ et al (2014) Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study. BMC Neurol 14:113. doi:10.1186/1471-2377-14-113

    Article  PubMed  PubMed Central  Google Scholar 

  25. Skogseth RE, Bronnick K, Pereira JB, Mollenhauer B, Weintraub D, Fladby T et al (2015) Associations between cerebrospinal fluid biomarkers and cognition in early untreated Parkinson’s disease. J Parkinsons Dis 5:783–792

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Compta Y, Buongiorno M, Bargalló N, Valldeoriola F, Muñoz E, Tolosa E et al (2016) White matter hyperintensities, cerebrospinal amyloid-beta and dementia in Parkinson’s disease. J Neurol Sci 367:284–290

    Article  CAS  PubMed  Google Scholar 

  27. Buongiorno M, Antonelli F, Compta Y, Fernandez Y, Pavia J, Lomeña F et al (2017) Cross-sectional and longitudinal cognitive correlates of FDDNP PET and CSF amyloid-beta and tau in Parkinson’s disease. J Alzheimers Dis 55:1261–1272

    Article  CAS  PubMed  Google Scholar 

  28. Schrag A, Siddiqui UF, Anastasiou Z, Weintraub D, Schott JM (2017) Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson’s disease: a cohort study. Lancet Neurol 16:66–75

    Article  CAS  PubMed  Google Scholar 

  29. Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P et al (2017) Cerebrospinal fluid Abeta42/40 corresponds better than Abeta42 to amyloid PET in Alzheimer’s disease. J Alzheimers Dis 55:813–822

    Article  CAS  PubMed  Google Scholar 

  30. Stewart T, Liu C, Ginghina C, Cain KC, Auinger P, Cholerton B et al (2014) Cerebrospinal fluid alpha-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol 184:966–975

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Leaver K, Poston KL (2015) Do CSF biomarkers predict progression to cognitive impairment in Parkinson’s disease patients? A systematic review. Neuropsychol Rev 25:411–423

    Article  PubMed  PubMed Central  Google Scholar 

  32. Wills J, Jones J, Haggerty T, Duka V, Joyce JN, Sidhu A (2010) Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson’s disease brains with and without dementia. Exp Neurol 225:210–218

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Haggerty T, Credle J, Rodriguez O, Wills J, Oaks AW, Masliah E et al (2011) Hyperphosphorylated tau in an alpha-synuclein-overexpressing transgenic model of Parkinson’s disease. Eur J Neurosci 33:1598–1610

    Article  PubMed  PubMed Central  Google Scholar 

  34. Caspell-Garcia C, Simuni T, Tosun-Turgut D, Wu IW, Zhang Y, Nalls M et al (2017) Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. PLoS One 12:e0175674. doi:10.1371/journal.pone.0175674

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. Xiaohui Hu and Yan Yang contributed equally to this work.

Authors and Affiliations

  1. Department of Neurology, Jingzhou Central Hospital, Tongji Medical College, Huazhong University of Science Technology, Renming Road No. 1, Jingzhou, 434020, China

    Xiaohui Hu & Daokai Gong

  2. Hubei College of Chinese Medicine, Jingzhou, China

    Yan Yang

Authors
  1. Xiaohui Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yan Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daokai Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daokai Gong.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Funding

The research is supported by Jingzhou Science and Technology Bureau Foundation (grant number 2016073).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hu, X., Yang, Y. & Gong, D. Changes of cerebrospinal fluid Aβ42, t-tau, and p-tau in Parkinson’s disease patients with cognitive impairment relative to those with normal cognition: a meta-analysis. Neurol Sci 38, 1953–1961 (2017). https://doi.org/10.1007/s10072-017-3088-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-017-3088-1

Keywords

Search

Navigation